Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133.2 USD | -1.15% | -0.25% | +1.05% |
Financials (USD)
Sales 2024 * | 2.22B | Sales 2025 * | 2.55B | Capitalization | 13.56B |
---|---|---|---|---|---|
Net income 2024 * | 431M | Net income 2025 * | 675M | EV / Sales 2024 * | 5.21 x |
Net cash position 2024 * | 2B | Net cash position 2025 * | 2.81B | EV / Sales 2025 * | 4.21 x |
P/E ratio 2024 * |
33.2
x | P/E ratio 2025 * |
21.2
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -1.15% | ||
1 week | -4.84% | ||
Current month | -1.67% | ||
1 month | -2.60% | ||
3 months | -4.36% | ||
6 months | +13.53% | ||
Current year | +1.05% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 208 M€ | +13.57% | - | |
3.81% | 1 M€ | +0.84% | - | |
1.85% | 7 M€ | +5.53% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 133.2 | -1.15% | 550,788 |
24-06-10 | 134.7 | -0.20% | 475,816 |
24-06-07 | 135 | +1.43% | 496,138 |
24-06-06 | 133.1 | -0.46% | 892,749 |
24-06-05 | 133.7 | +0.16% | 779,166 |
Delayed Quote Nasdaq, June 11, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.05% | 13.56B | |
+18.34% | 125B | |
+15.06% | 108B | |
-6.39% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.07% | 16.34B | |
+25.87% | 11.59B | |
+99.65% | 9.66B |
- Stock Market
- Equities
- NBIX Stock